METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS
    2.
    发明申请
    METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS 审中-公开
    生产适用于稳定的T细胞的细胞群体的方法

    公开(公告)号:US20170022478A1

    公开(公告)日:2017-01-26

    申请号:US15284840

    申请日:2016-10-04

    IPC分类号: C12N5/0783 A61K35/17

    摘要: The present invention provides methods for producing cell populations enriched for stable, regulatory T cells (Tregs). In particular, the invention relates to methods for culturing T cells such that the final culture is enriched for stable, regulatory T cells. It also relates to methods for stabilizing regulatory T cells. Also provided are compositions enriched for stable, regulatory T cells, which are useful for treating individuals in need of such treatment. The methods and compositions disclosed herein can also be used to treat an individual suffering from an immune-mediated disease.

    摘要翻译: 本发明提供用于产生富含稳定的调节性T细胞(Treg)的细胞群的方法。 特别地,本发明涉及培养T细胞的方法,使得最终培养物富集稳定的调节性T细胞。 它还涉及用于稳定调节性T细胞的方法。 还提供了富含稳定的调节性T细胞的组合物,其可用于治疗需要这种治疗的个体。 本文公开的方法和组合物还可以用于治疗患有免疫介导的疾病的个体。

    Platform of dendritic cell (DC)-based vaccination
    4.
    发明授权
    Platform of dendritic cell (DC)-based vaccination 失效
    基于树突状细胞(DC)的疫苗接种平台

    公开(公告)号:US08691570B2

    公开(公告)日:2014-04-08

    申请号:US13750850

    申请日:2013-01-25

    申请人: Pawel Kalinski

    发明人: Pawel Kalinski

    IPC分类号: C12N5/071 C12N5/00 C12N5/02

    摘要: The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.

    摘要翻译: 本发明公开了新颖的树突状细胞成熟诱导细胞因子鸡尾酒,以及用于在无血清条件下诱导1型偏振树突状细胞的方法,其增强了血清补充培养物中产生的DC1的期望性质。 本发明进一步公开了使用IFNγ和IFNγ受体的其它配体与IFNα(或其他I型干扰素),poly I:C和其他IFNα(和IFN和bgr)诱导剂组合以增强IL-12- 产生树突状细胞的性质。 更具体地,本发明公开了具有完全成熟状态和升高而不是“耗尽”生产IL-12p70能力的独特组合的1型偏振树突状细胞。 允许在无血清AIM-V培养基中产生完全成熟的DC1。 本发明公开了使用上述产物和方法促进基于DC1的疫苗的临床应用以及涉及DC1诱导Th1和CTL应答的新因子的鉴定的系统。

    Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells
    10.
    发明申请
    Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells 审中-公开
    通过共价连接抗原对树突状细胞表面的蛋白质增强免疫原性的方法

    公开(公告)号:US20030118569A1

    公开(公告)日:2003-06-26

    申请号:US10323338

    申请日:2002-12-18

    摘要: A method is provided to increase the immunogenicity of an antigen. This method involves the covalent coupling of the antigen to proteins or glycoproteins present on the surface of dendritic cells by a mild biochemical modification which minimizes the denaturation of the antigen and preserving cell viability. Dendritic cells with covalently linked antigen on their surface can be used for generating a specific response to the antigen. The present method can be used for both therapeutic and preventive purposes.

    摘要翻译: 提供了提高抗原免疫原性的方法。 该方法涉及通过温和的生物化学修饰将抗原与存在于树突状细胞表面上的蛋白质或糖蛋白共价偶联,其使抗原变性最小化并保持细胞活力。 在其表面上具有共价连接的抗原的树突状细胞可用于产生对抗原的特异性应答。 本方法可用于治疗和预防目的。